Dual single-port laparoscopic surgery for metastatic low-grade serous ovarian carcinoma: a case report of an innovative minimally invasive approach adhering to no-touch isolation technique

The management of peritoneal metastases in young patients with ovarian cancer demands a delicate balance between oncological radicality and quality of life. We present the case of a 34-year-old woman with a final pathological diagnosis of primary advanced-stage (FIGO IIIC) low-grade serous ovarian carcinoma (LGSC) of the left ovary, with metastases to the sigmoid colon, pelvic peritoneum, vesical peritoneum, diaphragm, and omental surface. The diagnosis was confirmed by comprehensive immunohistochemistry (PAX8+, WT1+, ER+, PR+, CA125+, p53 wild-type) and complete histopathological examination. To strictly comply with the “no-touch” isolation principle while maximizing the advantages of minimally invasive surgery, we successfully performed a novel dual single-port laparoscopic cytoreductive procedure. The operation encompassed anterior resection, left salpingo-oophorectomy, omentectomy, and peritonectomy, all accomplished through two discrete 4–5 cm single-port incisions, Each platform housed three channels: one for the camera and two for working instruments, facilitating complex multivisceral and peritoneal resections. Complete macroscopic cytoreduction (R0) was achieved, with negative resection margins and only one positive lymph node among three harvested.This case demonstrates the technical feasibility and short-term safety of this innovative approach in a carefully selected patient with advanced ovarian cancer and peritoneal dissemination. However, the short follow-up period is a major limitation, and long-term oncological equivalence or superiority over standard approaches cannot be claimed. The purported advantages regarding reduced tumor manipulation, lower port-site metastasis risk, and superior recovery remain hypothetical and require validation in larger studies. We are continuing surveillance to assess longer-term outcomes.